We support therapeutic development from early discovery to IND-enabling studies and GMP-ready potency assays—specializing in oncology, immuno-oncology, inflammation, and autoimmune disease. Our focus spans cutting-edge modalities including antibodies, cell therapies, nanoparticles, degraders, peptides, vaccines, and more. At the heart of RoukenBio is innovation—like IndEx-2, our customizable inducible cell line platform—and a “scientific empathy” approach that ensures your goals become ours. We recreate disease pathology as closely as possible, combining precision with partnership to advance next-generation therapeutics.